Last reviewed · How we verify

NCT05439746

A Study to Evaluate the Efficacy of Microlyte Matrix in the Management of Donor Site Wounds

Status unknown NA Last updated 28 October 2022
What this trial tests

NA trial testing Microlyte® Matrix in Wounds and Injuries in 53 participants. Status unknown.

Timeline
1 January 2023
Primary endpoint
30 January 2024
30 January 2024

Quick facts

Lead sponsorImbed Biosciences
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment53
Start date1 January 2023
Primary completion30 January 2024
Estimated completion30 January 2024

Drugs / interventions tested

Conditions studied

Sponsor

Imbed Biosciences

Who can join

Adults 18 to 65, any sex, with Wounds and Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study to to evaluate the efficacy of Microlyte® Matrix by demonstrating its superiority to the standard of care in the healing of donor site wounds in patients requiring split-thickness grafting, as well as to assess the occurrence of donor site wound infection, allergic reaction, pain and itching, and scarring at 12 weeks, assessed by patients using the Patient and Observer Scar Assessment Scale (POSAS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Wounds and Injuries

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05439746.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing